Buscar
Mostrando ítems 21-24 de 24
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
(Elsevier, 2021-01-31)
Background. Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on ...
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity
(Nature Research, 2024-02-05)
Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing
human monoclonal antibody isolated from a COVID-19 convalescent individual infected during the first pandemic wave. 17T2 is a ...
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models
(Nature Research, 2024-02-27)
AgeisassociatedwithreducedefficacyofvaccinesandlinkedtohigherriskofsevereCOVID-19.Herewe
determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike
glycoprotein ...
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection
(Nature Research, 2024-03-21)
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccines are crucial to fight against the coronavirus disease 2019
pandemic. Most vaccines are based on a mutated version ...